New Indications for TIPSs: What Do We Know So Far?

被引:7
|
作者
Lapenna, Lucia [1 ]
Di Cola, Simone [1 ]
Gazda, Jakub [2 ,3 ]
De Felice, Ilaria [1 ]
Gioia, Stefania [1 ]
Merli, Manuela [1 ]
机构
[1] Sapienza Univ Rome, Dept Translat & Precis Med, Rome, Italy
[2] Safarik Univ, Dept Internal Med 2, Kosice, Slovakia
[3] L Pasteur Univ Hosp Kosice, Kosice, Slovakia
关键词
transjugular intrahepatic portosystemic shunt; portal hyperten-sion; surgery; portal vein thrombosis; Budd-Chiari syndrome; INTRAHEPATIC PORTOSYSTEMIC SHUNT; PORTAL-VEIN THROMBOSIS; PARACENTESIS PLUS ALBUMIN; BUDD-CHIARI-SYNDROME; CIRRHOTIC-PATIENTS; REFRACTORY ASCITES; HEPATIC-ENCEPHALOPATHY; RISK-FACTOR; NONHEPATIC SURGERY; LIVER-CIRRHOSIS;
D O I
10.1016/j.jceh.2023.01.017
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Since 1988, transjugular intrahepatic portosystemic shunt (TIPS) has been an effective therapy for portal hypertension in many settings. Thanks to continuous technical improvements and a wiser selection of patients, excellent results have been achieved with this therapeutic strategy. The historical indications for TIPS placement, in the context of liver cirrhosis, such as refractory ascites and variceal bleeding are now well established and known. However, in recent years, new indications are emerging. These have been investigated and approved in some studies but are not yet included in guidelines and clinical practice. This review aims to highlight what is new for the role of TIPS in portal vein thrombosis (especially in patients awaiting liver transplantation), in recurrent ascites and not only refractory ascites, as a neoadjuvant therapy before abdominal surgery and, finally, in the setting of noncirrhotic portal hypertension. All these new aspects are addressed in this review with a critical approach based on the literature revision and clinical practice. Future research is needed to explore and validate the new role of TIPS in these scenarios. ( J CLIN EXP HEPATOL 2023;13:794-803)
引用
收藏
页码:794 / 803
页数:10
相关论文
共 50 条
  • [11] Neuroproteomics in Epilepsy: What Do We Know so Far?
    do Canto, Amanda M.
    Donatti, Amanda
    Geraldis, Jaqueline C.
    Godoi, Alexandre B.
    da Rosa, Douglas C.
    Lopes-Cendes, Iscia
    FRONTIERS IN MOLECULAR NEUROSCIENCE, 2021, 13
  • [12] China coronavirus: what do we know so far?
    Mahase, Elisabeth
    BMJ-BRITISH MEDICAL JOURNAL, 2020, 368 : m308
  • [13] Refractory hypertension: what do we know so far?
    Muxfeldt, Elizabeth Silaid
    Chedier, Bernardo
    JOURNAL OF HUMAN HYPERTENSION, 2021, 35 (03) : 181 - 183
  • [14] Exosomes in Retinoblastoma: What do we know so far?
    Kaliki, Swathi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2023, 64 (08)
  • [15] Fetal nephrolithiasis: What do we know so far?
    Petrovic, Oleg
    Raspor, Sanja Flajsman
    Krajina, Robert
    Ivandic, Jelena
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2024, 165 (01) : 385 - 387
  • [16] What we know so far
    不详
    NEW SCIENTIST, 2021, 245 (3347) : 8 - 8
  • [17] What we know so far
    Gazzard, B
    AIDS, 1996, 10 : S3 - S7
  • [18] Lisfranc Sports Injuries: What Do We Know So Far?
    Maduka, Godsfavour C.
    Maduka, Divinegrace C.
    Yusuf, Naeem
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (11)
  • [19] What do we know about DNA mechanics so far?
    Aggarwal, Abhishek
    Naskar, Supriyo
    Sahoo, Anil Kumar
    Mogurampelly, Santosh
    Garai, Ashok
    Maiti, Prabal K.
    CURRENT OPINION IN STRUCTURAL BIOLOGY, 2020, 64 : 42 - 50
  • [20] Leishmaniasis in transplant patients: what do we know so far?
    Monge-Maillo, Begona
    Lopez-Velez, Rogelio
    CURRENT OPINION IN INFECTIOUS DISEASES, 2024, 37 (05) : 342 - 348